Abstract
Voluntary communication by a manufacturer, distributor or health authority to inform health professionals of an unreasonable risk to the public health by a commercialised medicinal product or device intended for human use; this may be followed by a Type II variation procedure; see also urgent safety measures, urgent safety restriction.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Nahler, G. (2017). S. In: Dictionary of Pharmaceutical Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-50669-2_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-50669-2_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-50668-5
Online ISBN: 978-3-319-50669-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)